About ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.
|
|
|
51-200 employees
View all ReCode Therapeutics employees
|
|
Biotechnology
|
|
Menlo Park, California & Dallas, Texas, US
|
|
2015
|
|
Biotechnology, Cystic Fibrosis, Cystic Fibrosis, Genetic Medicines, Genetic Respiratory Disease, Non-Viral Lipid Nanoparticles, Primary Ciliary Dyskinesia, Rna Therapies, Primary Ciliary Dyskinesia, Biotechnology, Genetic Medicines
|
ReCode Therapeutics Alternatives
Frequently Asked Questions about ReCode Therapeutics
Jessica Kelly is the CEO of ReCode Therapeutics. To contact Jessica Kelly email at [email protected] or [email protected]. Or you may call (650)740-7615 or 18508324932
ReCode Therapeutics Staff Directory
Search ReCode Therapeutics Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
